Clinical Trials

47 enrolled

Lung Neoplasms

NCT06591650 2026-05-14

GCND

GastrointestinalGenitourinary

33 enrolled

Gallbladder Cancer Unresectable

NCT03606967 2026-05-13

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

70 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03907475 2026-05-13

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

115 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04379596 2026-05-13

DG-03

450 enrolled

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT07012798 2026-05-13

FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma

30 enrolled

Carcinoma, Hepatocellular

NCT04918186 2026-05-12

IPROC

60 enrolled

Gynecologic

Ovarian Neoplasms

NCT07081633 2026-05-12

TREMENDOUS-2

114 enrolled

Carcinoma, Hepatocellular

NCT03459846 2026-05-11

BAYOU

154 enrolled 13 charts

Genitourinary

Urinary Bladder Neoplasms

NCT03601455 2026-05-11

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

13 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT04716946 2026-05-11

Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy

13 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06667908 2026-05-11

CONVERGE

130 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05092412 2026-05-08

Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC

30 enrolled

Lung Neoplasms, Small Cell Lung Carcinoma

NCT06290505 2026-05-08

PALEO

54 enrolled

Esophageal Neoplasms

NCT06728410 2026-05-08

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

38 enrolled

Cholangiocarcinoma

NCT01042379 2026-05-06

I-SPY

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT05027425 2026-05-06

Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

Phase 2 Terminated

8 enrolled 9 charts

Fibrosis, Carcinoma, Hepatocellular, Hypertension, Portal

NCT06094140 2026-05-06

NEO-IMPACT

20 enrolled

Pancreatic Neoplasms

NCT06441747 2026-05-06

Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

40 enrolled

Phase 2 Not yet recruiting

Cholangiocarcinoma

NCT07146230 2026-05-06

SPRINT 2

52 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04786093 2026-05-05

Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC

Phase 2 Terminated

1 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT07122089 2026-05-05

IOSPHERE

80 enrolled

Phase 2 Not yet recruiting

Carcinoma, Hepatocellular

NCT07226063 2026-05-05

Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer

16 enrolled

Phase 2 Not yet recruiting

Carcinoma, Hepatocellular, Liver Neoplasms

NCT07247786 2026-05-05

MIGRANT

68 enrolled

Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms

NCT03482102 2026-05-04

Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer

37 enrolled

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

NCT03660826 2026-05-04

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone